Evidence map›Paper›PMID 23911560›Full record

Trial reportJournal of minimally invasive gynecology

Lymphadenectomy in locally advanced cervical cancer study (LiLACS): Phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2-IVA cervical cancer.

Michael Frumovitz, Denis Querleu, Antonio Gil-Moreno, Philippe Morice, Anuja Jhingran, Mark F Munsell, Homer A Macapinlac, Eric Leblanc, Alejandra Martinez, Pedro T Ramirez

2 registry-linked trialsAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of minimally invasive gynecology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 32 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04555226 narecruitingnot on this map

Randomized Controlled Trial of the Efficacy of Lymph Node Dissection on Stage IIICr of Cervical Cancer

TypeinterventionalSponsorChongqing University Cancer HospitalRan2021 to 2032Enrolled452ConditionsCervical CancerArmsLymph node dissection, Standard chemoradiation±pembrolizumab, Chemoradiation± pembrolizumab
NCT05378087 narecruitingnot on this map

Non-randomized Concurrent Controlled Trial of Surgery Staging or Image Staging of Locally Advanced Cervical Cancer

TypeinterventionalSponsorChongqing University Cancer HospitalRan2022 to 2032Enrolled1,956ConditionsLocally Advanced Cervical CancerArmsConcurrent chemoradiation, Open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation
3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. Multicentric development and evaluation ofEuropean journal of nuclear medicine and molecular imaging · 2023
    Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Radiation oncology management of stage III and IVA cervical carcinoma.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022
    Review
  15. Value of PET imaging for radiation therapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021
    Review
  16. Review
  17. Review
  18. False negative rate atBMC cancer · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Michael FrumovitzDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: mfrumovitz@mdanderson.org.
Denis QuerleuDepartment of Surgical Oncology, Claudius Regaud Comprehensive Cancer Center, Toulouse, France.
Antonio Gil-MorenoDepartment of Gynecologic Oncology, Hospital Vall d'Hebron, Barcelona, Spain.
Philippe MoriceDepartment of Surgery, Institut Gustave Roussy, Paris, France.
Anuja JhingranDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mark F MunsellDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Homer A MacapinlacDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Eric LeblancDepartment of Gynecologic Oncology, Oscar Lambret Cancer Center, Lille, France.
Alejandra MartinezDepartment of Surgical Oncology, Claudius Regaud Comprehensive Cancer Center, Toulouse, France.
Pedro T RamirezDepartment of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · USInstitut Claudius Regaud · FRCentre Oscar Lambret · FRInstitut Gustave Roussy · FRVall d'Hebron Hospital Universitari · ES

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Radiation treatment planning for women with locally advanced cervical cancer (stages IB2-IVA) is often based on positron emission tomography (PET). PET, however, has poor sensitivity in detecting metastases in aortocaval nodes. We have initiated a study with the objective of determining whether pre-therapeutic laparoscopic surgical staging followed by tailored chemoradiation improves survival as compared with PET/computed tomography (CT) radiologic staging alone followed by chemoradiation. This international, multicenter phase III trial will enroll 600 women with stages IB2-IVA cervical cancer and PET/CT findings showing fluorodeoxyglucose-avid pelvic nodes and fluorodeoxyglucose-negative para-aortic nodes. Eligible patients will be randomized to undergo either pelvic radiotherapy with chemotherapy (standard-of-care arm) or surgical staging via a minimally invasive extraperitoneal approach followed by tailored radiotherapy with chemotherapy (experimental arm). The primary end point is overall survival. Secondary end points are disease-free survival, short- and long-term morbidity with pre-therapeutic surgical staging, and determination of anatomic locations of metastatic para-aortic nodes in relationship to the inferior mesenteric artery. We believe this study will show that tailored chemoradiation after pre-therapeutic surgical staging improves survival as compared with chemoradiation based on PET/CT in women with stages IB2-IVA cervical cancer.

Indexed as

Tomography, Emission-ComputedClinical ProtocolsDisease-Free SurvivalFemaleFluorodeoxyglucose F18HumansLymphatic MetastasisLymph Node ExcisionResearch DesignUterine Cervical NeoplasmsFluorodeoxyglucose F18CervixLaparoscopyPET/CTSurgical staging

Identifiers

PMID23911560
PMCPMC4283493
OpenAlexW2084595177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.